Shots: The P-III study will assess the efficacy, safety and tolerability of Aflibercept (intravitreal) in ~100 infants with ROP across 34 countries Bayer & Regeneron collaborated to develop aflibercept whereas […]readmore
Tags : aflibercept
Regulatory
Regeneron’s Eylea (aflibercept) Injection Receives FDA’s Approval for Diabetic Retinopathy
Shots: The approval is based on P-III PANORAMA study results assessing Eylea (q8w, q16w) vs sham in 402 patients with non-proliferative diabetic retinopathy (NPDR) without diabetic macular edema (DME) The […]readmore
Shots: The P-III PANORAMA Trial involves assessing of Eylea (aflibercept) vs sham injection in 402 patients with moderately severe to severe NPDR in without DME for 16 wks. or 8 […]readmore
Shots: The P-III PANORAMA trial involves assessing of Eylea (q8w, q16w) vs PBO (sham injection) in 402 patients with moderately-severe and severe NPDR for 52 weeks P-III PANORAMA trial results: […]readmore